Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141302 | 0.93 | RET (0.34) | RETSMYD3GABRA2GABRB2HRH4 | |
| SCHEMBL18161139 | 0.92 | PSMB8 (0.35) | RETSMYD3GABRA2GABRB2DRD2 | |
| SCHEMBL12203587 | 0.92 | HRH4 (0.37) | RETGABRA2GABRB2HRH4PSMB8 | |
| SCHEMBL19625281 | 0.91 | HRH4 (0.39) | RETGABRA2GABRB2HRH4PSMB8 | |
| SCHEMBL18367634 | 0.90 | DRD2 (0.33) | RETSMYD3GABRA2GABRB2DRD2 | |
| SCHEMBL18367573 | 0.88 | CNR2 (0.38) | RETGABRA2GABRB2 | |
| SCHEMBL19589565 | 0.88 | CHRNB2 (0.36) | RETGABRA2GABRB2HRH4HRH3 | |
| SCHEMBL18367582 | 0.86 | DRD2 (0.33) | RETGABRA2GABRB2DRD2DRD4 | |
| SCHEMBL18367602 | 0.84 | DRD4 (0.40) | DRD2DRD4KCNH2SIGMAR1DRD3 | |
| SCHEMBL18367629 | 0.84 | GSK3B (0.36) | RETDRD2DRD4KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | RET 423/4885SMYD3 1000/4885GABRA2 2029/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | RET 423/4885SMYD3 1000/4885GABRA2 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.